Paper393427
m-AMSA and PALA: two new agents in cancer chemotherapy.
Rozencweig M and 3 others. Cancer Chemother Pharmacol, 1979. Cited by 23 papers, by iCite.
Cite this record
ConductScience Library. m-AMSA and PALA: two new agents in cancer chemotherapy. Papers, record 393427. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/393427
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aminoacridines | Major topic |
| Antineoplastic Agents | Major topic |
| Aspartic Acid | Major topic |
| Organophosphorus Compounds | Major topic |
| Phosphonoacetic Acid | Major topic |
| Animals | |
| Cell Division | |
| Kinetics | |
| Neoplasms, Experimental |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 204947 | Oral absorption and selective tissue localization of 4'-(9-acridinylamino)-methanesulfon-m-anisidide. | Pharmacology | 1978 | https://conductscience.org/library/papers/204947 | PubMed |
| 2 | 4463003 | The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. | Eur J Cancer (1965) | 1974 | https://conductscience.org/library/papers/4463003 | PubMed |
| 3 | 476706 | Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA). | Cancer Treat Rep | 1979 | https://conductscience.org/library/papers/476706 | PubMed |
| 4 | 328129 | VM 26 and VP 16-213: a comparative analysis. | Cancer | 1977 | https://conductscience.org/library/papers/328129 | PubMed |
| 5 | 76512 | Interaction of 4'-(9-acridinylamino)methanesulfon-m-anisidide with DNA and inhibition of oncornavirus reverse transcriptase and cellular nucleic acid polymerases. | Cancer Res | 1978 | https://conductscience.org/library/papers/76512 | PubMed |
| 6 | 15938285 | Comparative activities of aspartate transcarbamylase in various tissues of the rat. | Proc Soc Exp Biol Med | 1967 | https://conductscience.org/library/papers/15938285 | PubMed |
| 7 | 21782 | The pharmacologic disposition of 4'-(9-acridinylamino)methanesulfon-m-anisidide in mice and rats. | Drug Metab Dispos | 1977 | https://conductscience.org/library/papers/21782 | PubMed |
| 8 | 4348752 | The use of drugs in combination for the treatment of cancer: rationale and results. | N Engl J Med | 1973 | https://conductscience.org/library/papers/4348752 | PubMed |
| 9 | 280145 | Antiviral activities of 4'-(9-acridinylamino)-methanesulfon-M-aniside (SN11841). | Ann N Y Acad Sci | 1977 | https://conductscience.org/library/papers/280145 | PubMed |
| 10 | 750106 | The clinical evaluation of analogues. I. The overall problem. | Cancer Chemother Pharmacol | 1978 | https://conductscience.org/library/papers/750106 | PubMed |
| 11 | 1034560 | DNA-binding characteristics of acridinylmethanesulphonanilide drugs: comparison with antitumour properties. | Eur J Cancer (1965) | 1976 | https://conductscience.org/library/papers/1034560 | PubMed |
| 12 | 7055806 | Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration. | Cancer Res | 1982 | https://conductscience.org/library/papers/7055806 | PubMed |
| 13 | 890691 | Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents. | Cancer Treat Rep | 1977 | https://conductscience.org/library/papers/890691 | PubMed |
| 14 | 361225 | An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues. | Cancer Treat Rep | 1978 | https://conductscience.org/library/papers/361225 | PubMed |
| 15 | 831730 | Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo. | Biochem Pharmacol | 1977 | https://conductscience.org/library/papers/831730 | PubMed |
| 16 | 12870 | Stable mutants of mammalian cells that overproduce the first three enzymes of pyrimidine nucleotide biosynthesis. | Cell | 1976 | https://conductscience.org/library/papers/12870 | PubMed |
| 17 | 279397 | Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative. | Cancer Res | 1978 | https://conductscience.org/library/papers/279397 | PubMed |
| 18 | 4609763 | An assessment of the immunosuppressive activity of the anti-tumour compound--4'-((9-acridinyl)amino)methanesulphon-m-anisidide (m-AMSA). | Eur J Cancer (1965) | 1974 | https://conductscience.org/library/papers/4609763 | PubMed |
| 19 | 144557 | Chemotherapy of human colon cancer xenografts in athymic nude mice. | Cancer | 1977 | https://conductscience.org/library/papers/144557 | PubMed |
| 20 | 361222 | Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule. | Cancer Treat Rep | 1978 | https://conductscience.org/library/papers/361222 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 27893848 | The Open Form Inducer Approach for Structure-Based Drug Design. | PLoS One | 2016 | https://conductscience.org/library/papers/27893848 | PubMed |
| 6896455 | Clonal variation in the sensitivity of B16 melanoma to m-AMSA. | Br J Cancer | 1982 | https://conductscience.org/library/papers/6896455 | PubMed |
| 6893934 | Enhanced killing of mammalian cells by radiation combined with m-AMSA. | Br J Cancer | 1980 | https://conductscience.org/library/papers/6893934 | PubMed |
| 6688382 | Influence of scheduling on therapeutic and toxic effect of AMSA in Lewis lung carcinoma. | Cancer Chemother Pharmacol | 1983 | https://conductscience.org/library/papers/6688382 | PubMed |
| 6549551 | Effectiveness of AMSA alone or in combination with radiation on murine fibrosarcoma pulmonary nodules. | Clin Exp Metastasis | 1984 | https://conductscience.org/library/papers/6549551 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/393427
GET https://conductscience.org/api/papers/v1/393427/references?page=2